Cargando…
Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590806/ https://www.ncbi.nlm.nih.gov/pubmed/26555987 http://dx.doi.org/10.1155/2013/583536 |
_version_ | 1782392983660789760 |
---|---|
author | Sravya, Maddukuri Deveswaran, Rajamanickam Bharath, Srinivasan Basavaraj, Basappa Veerbadraiah Madhavan, Varadharajan |
author_facet | Sravya, Maddukuri Deveswaran, Rajamanickam Bharath, Srinivasan Basavaraj, Basappa Veerbadraiah Madhavan, Varadharajan |
author_sort | Sravya, Maddukuri |
collection | PubMed |
description | The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1 : 5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs. |
format | Online Article Text |
id | pubmed-4590806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45908062015-10-13 Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex Sravya, Maddukuri Deveswaran, Rajamanickam Bharath, Srinivasan Basavaraj, Basappa Veerbadraiah Madhavan, Varadharajan J Pharm (Cairo) Research Article The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1 : 5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs. Hindawi Publishing Corporation 2013 2013-09-24 /pmc/articles/PMC4590806/ /pubmed/26555987 http://dx.doi.org/10.1155/2013/583536 Text en Copyright © 2013 Maddukuri Sravya et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sravya, Maddukuri Deveswaran, Rajamanickam Bharath, Srinivasan Basavaraj, Basappa Veerbadraiah Madhavan, Varadharajan Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title | Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title_full | Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title_fullStr | Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title_full_unstemmed | Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title_short | Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex |
title_sort | development of orodispersible tablets of candesartan cilexetil-β-cyclodextrin complex |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590806/ https://www.ncbi.nlm.nih.gov/pubmed/26555987 http://dx.doi.org/10.1155/2013/583536 |
work_keys_str_mv | AT sravyamaddukuri developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex AT deveswaranrajamanickam developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex AT bharathsrinivasan developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex AT basavarajbasappaveerbadraiah developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex AT madhavanvaradharajan developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex |